(Q40429865)

20 September 2017

1 reference

title

Multiple sclerosis: TNF revisited, with promise (English)

1 reference

20 September 2017

0 references

0 references

C. S. Raine

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7585035

25 May 2024

language of work or name

English

0 references

publication date

1 March 1995

1 reference

full work available at URL

20 September 2017

http://www.nature.com/articles/nm0395-211

1 reference

https://api.crossref.org/works/10.1038/NM0395-211

http://www.nature.com/articles/nm0395-211.pdf

25 May 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NM0395-211

25 May 2024

1 reference

20 September 2017

volume

1

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

211-214

1 reference

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

Role of cytokines in determining T-lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Tumor necrosis factor identified in multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0395-211

7 January 2021

Identifiers

DOI

10.1038/NM0395-211

1 reference

20 September 2017

1 reference